Жарияланымдар / Публикации

Постоянный URI для этого сообществаhttps://cris.qyzpu.kz/handle/123456789/2

Просмотр

Результаты поиска

Показано: 1 - 4 из 4

Некоторые метрики заблокированы вашими
настройками согласия
Public health risks associated with antibiotic residues in poultry food products
(Elsevier BV, 2025-03-16)
Sylvester Chibueze Izah
;
Akmaral Nurmahanova
;
Matthew Chidozie Ogwu
;
Zhexenbek Toktarbay
;
Zoya Umirbayeva
Antibiotic residues in the poultry food products pose significant public health risks, contributing to the growing global challenge of antimicrobial resistance (AMR). This paper focuses on the public health risks associated with antibiotic residues in poultry food products. The study found that the routine use of antibiotics in poultry farming for growth promotion and disease prevention has resulted in the accumulation of residues in food products, which can lead to adverse health effects in consumers. These include allergic reactions, toxicity, disruption of gut microbiota, and the promotion of antibiotic-resistant bacteria. Long-term exposure to antibiotic residues, even at low levels, exacerbates these risks, impacting not only individual health but also broader public health systems. Regulatory frameworks, such as the establishment of maximum residue limits (MRLs) and stringent monitoring, are crucial for ensuring food safety. However, there is a pressing need for alternative strategies in poultry production that reduce reliance on antibiotics while maintaining animal health. Public education, antimicrobial stewardship, and sustainable farming practices are vital to mitigate the risks posed by antibiotic residues. The global effort to address AMR should involve coordinated actions among stakeholders, including policymakers, farmers, and healthcare providers, to protect both food safety and public health. Future research needs to prioritize the development of alternative therapeutics and innovative farming practices to minimize the presence of antibiotic residues in poultry products. • Use of antibiotics in poultry could boost growth and wellbeing but also pose public health risks. • Ongoing misuse is driving an increase in environmental and organismal antibiotic residues. • Antibiotic residues can accumulate through the food chain with known and unknown One Health effects. • Factors affecting residues include antibiotic type, dosage, withdrawal and cultural practices. • Cooking reduces antibiotic residues, but consumption of poultry products may cause allergic and microbiota effects.
Цитирования (OpenAlex) 38Цитирования (OpenCitations) 14
Некоторые метрики заблокированы вашими
настройками согласия
Multifunctional Peptides from Equine Milk Lactoferrin: Evaluation of Antimicrobial Activity In Silico and In Vitro
(Multidisciplinary Digital Publishing Institute, 2026-04-16)
Meiramkul Narmuratova
;
Shara Alpysbayevna Atambayeva
;
Gulzhan K. Kaiyrmanova
;
Saltanat Orazova
;
Gulzhan Narmuratova
The rapid global spread of antimicrobial resistance among pathogenic microorganisms poses a serious challenge to both human and animal health, underscoring the urgent need for new strategies to combat resistance. Antimicrobial peptides (AMPs), key components of the innate immune system, are promising candidates because they disrupt the membranes of bacteria, fungi, and viruses, thereby reducing the risk of resistance development. Lactoferrin (LF), a multifunctional iron-binding glycoprotein abundant in mammalian milk, is a rich source of AMPs. Cationic peptide fragments such as lactoferricin and lactoferrampin exhibit more potent direct antimicrobial activity than the intact protein. Our previous studies have shown that peptides derived from Equine milk lactoferrin exhibit antihypertensive, anti-inflammatory, and anti-oncogenic activity in silico, highlighting their multifunctional bioactive potential. Building on these results, the present study aims to investigate the antimicrobial properties of these peptides. We used an integrated approach combining computer modeling and in vitro studies to identify and validate novel antimicrobial peptides from equine milk lactoferrin. Bioinformatics tools, including AMPScanner and CAMP, were used to predict antimicrobial domains, followed by experimental testing against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. The results showed that equine milk lactoferrin peptides possess potent and selective antimicrobial activity, with efficacy varying across bacterial species. These data expand the functional profile of lactoferrin-derived peptides, demonstrating their multifunctionality, and suggest that equine milk lactoferrin represents a promising natural source of antimicrobial agents, supporting alternative strategies to reduce antibiotic use in human and veterinary medicine.
Цитирования (OpenAlex) 2
Некоторые метрики заблокированы вашими
настройками согласия
DEVELOPMENT, PHARMACEUTICAL EVALUATION, AND ASSESSMENT OF THE BACTERICIDAL ACTIVITY OF THE KC-250 TABLET FORMULATION AGAINST CLINICALLY SIGNIFICANT MICROORGANISMS
(2026-08-21)
Daniil Shepilov
;
Zhassur Taganov
;
Ardak B. Jumagaziyeva
;
Sabina T. Kenesheva
;
Saltanat Jumabayeva
Introduction: Conversion of iodine-containing complexes into solid dosage forms requires adequate tablet strength while preserving disintegration, release, and antimicrobial activity. This study aimed to develop a directly compressed KC-250 tablet formulation, evaluate its pharmaceutical quality, and determine its bactericidal activity against clinically significant bacteria. Methods: Tablets containing 60 mg of KC-250 at a target mass of 500 mg were prepared using MicroceLac® 100, povidone K30, and magnesium stearate. Compression forces of 3.24 and 6.96 kN were compared by friability and disintegration testing. The selected formulation was evaluated for pharmacopoeial quality attributes. Bactericidal activity against eight reference, resistant, and clinical bacterial strains was determined in triplicate by broth serial dilution followed by agar subculture. Results: Increasing compression force from 3.24 to 6.96 kN reduced friability from 0.81% to 0.21%, while disintegration increased from 1.62 to 4.62 min. Tablets produced at 6.96 kN had friability of 0.20%, a disintegration time of 4 min 54 s, a KC-250 content of 63.05 mg/tablet, and dissolution of 102.95% within 45 min. All evaluated attributes complied with the predefined acceptance criteria. Minimum bactericidal concentrations were 60 mg/mL for the tested Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa strains and 30 mg/mL for Enterococcus faecalis and Enterococcus faecium. Discussion: Compression at 6.96 kN provided the most appropriate balance between mechanical resistance and rapid disintegration without restricting KC-250 release. The retained bactericidal activity indicates that tablet formulation did not eliminate the antimicrobial function of KC-250 and supports further development of the selected MicroceLac® 100– povidone K30 matrix.
Некоторые метрики заблокированы вашими
настройками согласия
D/PVA/I-1 as an Antibiotic Adjuvant: In Vitro Synergy and Membrane Permeabilization in MDR Bacteria
(Multidisciplinary Digital Publishing Institute, 2026-08-17)
Ardak B. Jumagaziyeva
;
Seitzhan Turganbay
;
Anar Seisembekova
;
Daniil Shepilov
;
Zhanar A. Iskakbayeva
Background: Antimicrobial resistance (AMR) is among the most pressing challenges in modern infectious medicine, driving progressive failure of standard antibacterial therapy and rising mortality from infections caused by multidrug-resistant (MDR) pathogens. Antibiotic potentiation through adjuvant compounds capable of restoring the activity of existing drugs represents a promising strategy to overcome resistance without developing fundamentally new antibacterial molecules. This study aimed to evaluate the antibiotic-potentiating activity of a dextrin/polyvinyl alcohol/iodine complex (D/PVA/I-1), developed at the Scientific Center for Anti-Infectious Drugs JSC (Almaty, Kazakhstan), against clinically relevant MDR reference strains. Methods: Nine reference strains, Staphylococcus aureus (ATCC 33591, BAA-39), Escherichia coli (ATCC BAA-196, BAA-2523), Klebsiella pneumoniae (ATCC BAA-2524, 700603), Acinetobacter baumannii (ATCC BAA-1790), Streptococcus pneumoniae (ATCC BAA-660), and Haemophilus influenzae (ATCC 33930), and two clinical isolates, P. aeruginosa SCAID PHRX1-2019 and E. coli SCAID WND1-2021, were tested. Antibiotic-potentiating activity was assessed by checkerboard assay with calculation of the fractional inhibitory concentration index (FICI); bactericidal kinetics were evaluated by time-kill analysis. The effect of D/PVA/I-1 on cytoplasmic membrane permeability was investigated using a crystal violet uptake assay. Results: Of 45 D/PVA/I-1–antibiotic combinations tested across nine antibiotics, synergy (FICI ≤ 0.5) was demonstrated in 44.4% of cases, partial synergy in 48.9%, and additive effects in 6.7%; no antagonistic interactions were detected. The most pronounced potentiating effect occurred against Gram-positive pathogens, particularly MRSA strains (66.7% synergistic combinations). Time-kill analysis confirmed suppression of the regrowth phenotype characteristic of MDR strains under monotherapy and restoration of bactericidal activity against antibiotics to which strains exhibited intrinsic resistance. D/PVA/I-1 induced a dose- and time-dependent increase in membrane permeability in both Gram-positive and Gram-negative organisms. Conclusions: D/PVA/I-1 is an effective broad-spectrum antibiotic potentiator and represents a promising basis for combination therapy regimens against MDR infections.

Жарияланымдар / Публикации

Просмотр

Фильтры

Настройки

Сортировать по

результатов на странице

Результаты поиска

QyzPU CRIS

Университет

Данные